文献速递血栓与止血

伴抑制物A型血友病基因治疗原理综述:一次性免疫耐受与治疗?

A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
PubMed 文献 · J Thromb Haemost · 2023-05-22

本文综述伴抑制物A型血友病患者持续存在的未满足医疗需求、FVIII免疫耐受机制及最新耐受策略研究,并探讨肝导向基因治疗介导FVIII免疫耐受诱导的作用。约30%的重型A型血友病患者产生针对FVIII的抑制性抗体;艾美赛珠单抗可提供安全有效的出血预防,但临床仍在探索实现FVIII免疫耐受的治疗策略。

要点

  • 约30%的重型A型血友病患者产生针对FVIII的抑制性抗体。
  • 艾美赛珠单抗为许多A型血友病患者提供安全有效的出血预防。
  • 肝导向基因治疗作为新型免疫耐受诱导选项,提供内源性持续FVIII来源。

核心结论

  • 基因治疗作为新型免疫耐受诱导选项,可提供内源性、持续的FVIII来源。
  • 本文综述FVIII抑制物相关的持续未满足医疗需求、FVIII耐受免疫学、最新耐受策略研究及肝导向基因治疗介导FVIII免疫耐受诱导的作用。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 约30%的重型A型血友病患者产生针对FVIII的抑制性抗体。
  • 艾美赛珠单抗为许多A型血友病患者提供安全有效的出血预防。
  • 针对FVIII的免疫耐受诱导通常通过多种方案反复长期暴露于FVIII来完成。
  • 基因治疗近期作为新型免疫耐受诱导选项出现,提供内源性、持续的FVIII来源。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapeutic landscape for people living with hemophilia A (PwHA) has changed dramatically in recent years, but many clinical challenges remain, including the development of inhibitory antibodies directed against factor VIII (FVIII) that occur in approximately 30% of people with severe hemophilia A. Emicizumab, an FVIII mimetic bispecific monoclonal antibody, provides safe and effective bleeding prophylaxis for many PwHA, but clinicians still explore therapeutic strategies that result in immunologic tolerance to FVIII to enable effective treatment with FVIII for problematic bleeding events. This immune tolerance induction (ITI) to FVIII is typically accomplished through repeated long-term exposure to FVIII using a variety of protocols. Meanwhile, gene therapy has recently emerged as a novel ITI option that provides an intrinsic, consistent source of FVIII. As gene therapy and other therapies now expand therapeutic options for PwHA, we review the persistent unmet medical needs with respect to FVIII inhibitors and effective ITI in PwHA, the immunology of FVIII tolerization, the latest research on tolerization strategies, and the role of liver-directed gene therapy to mediate FVIII ITI.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Valentino LA, Ozelo MC, Herzog RW, et al. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment? J Thromb Haemost. 2023. PMID: 37225021. doi:10.1016/j.jtha.2023.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。